Hansa Biopharma
@HansaBiopharma
Followers
439
Following
21
Media
151
Statuses
208
Hansa Biopharma is a rare disease company, delivering and developing innovative and life-changing treatments for patients with rare immunological conditions.
Lund, Sweden
Joined January 2021
Today @HansaBiopharma is honoured to share Cris Ann’s story – one of determination and hope. Read more here: https://t.co/9SpHckdIEn Watch Cris Ann telling her story below and help raise awareness of the unmet need of highly sensitized kidney transplant patients.
0
1
5
For investors and media : Today Hansa announced positive topline results from the US Phase 3 ConfIdeS trial in kidney transplantation. https://t.co/Fx2ZqvfRUY
hansabiopharma.com
0
0
18
Today Hansa Biopharma published its Interim Financial Report for the second quarter and first half of 2025. Hansa will host a conference call today, 17 July, at 14:00 CEST / 8:00 am ET https://t.co/KvgqwvrYQ8
0
0
4
No matter the difficulties, Cris Ann – a highly sensitized kidney transplant patient - has a strong determination and hope that she will eventually receive a kidney transplant and go back to her career as a nurse.
0
0
5
Join us today on @HansaBiopharma's Autoimmune Deep Dive - Guillain-Barré Syndrome 14:00 CEST / 8:00 AM ET with KOLs David Cornblath, MD and Simon Rinaldi MRCP(Neuro), PhD, and Hansa R&D leadership to learn more about GBS disease. https://t.co/TxwM4d5oHJ
0
0
4
Cris Ann registered on the kidney transplant waiting list hoping to avoid dialysis. Then she learned she is one of the 10-15% of kidney transplant patients in the U.S. who are highly sensitized, making it virtually impossible to find a compatible donor kidney. #WorldTransplantDay
0
1
8
We look forward to hosting the Autoimmune Deep Dive Guillain-Barré Syndrome on 16 June. This is a virtual event aimed at investors and members of the press focusing on Guillain-Barré Syndrome (GBS). Learn more and register for the event at the link below. https://t.co/vYxKNeXQFZ
0
0
5
Follow us in the upcoming few weeks as we share Cris Ann’s story, and help us raise awareness of the unmet need of highly sensitized kidney transplant patients.
0
0
2
Cris Ann is a nurse, a mother of four, and a highly sensitized kidney transplant patient. She’s desperately trying to find a donor kidney that would allow her to live her life to the fullest. But with a cPRA of 100%, she has few chances to find a compatible organ.
2
0
3
Recently, Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity sat down with @neurology_live to discuss @HansaBiopharma's recent data in GBS and the potential positive impact of removing IgG in patients with GBS. Hear more at the clip below. https://t.co/7ntq8MGZFV
neurologylive.com
The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré...
0
1
4
GBS, is a severe acute disease that manifests suddenly with autoimmune response targeting peripheral nerves and spinal roots. GBS requires urgent medical attention. Approximately 100,000 people each year are diagnosed with GBS worldwide. Learn more: https://t.co/omob3C8lYX
0
0
3
This week we are attending @KidneyPatients’ 7th annual Global Summit on Kidney Innovations with a presentation by @HansaBiopharma and Syneos Health on understanding the preferences of highly sensitized kidney transplant patients #GlobalKidney2025
https://t.co/ANn4Hfqbrw
0
1
4
Earlier this month @HansaBiopharma's Chief R&D Officer was featured in a @PrecMedOnline article on AAV autoimmunity in gene therapy and the potential for our technology to help address this challenge. We remain excited for what’s to come in this space! https://t.co/ugJriSKo14
precisionmedicineonline.com
From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder gene therapy response.
0
0
2
We look forward to joining @PNSociety1 #PNS2025 Annual Meeting this weekend, hearing from experts on the latest advancements in peripheral neuropathy. Data from Hansa’s Phase 2 study in GBS will be also discussed in an oral presentation. https://t.co/8OMjjDTFuh
0
0
5
Hansa Biopharma’s technology was recently featured in a Forbes article on innovation in autoimmune disease treatment, including remarks from Hansa’s Chief R&D Officer Hitto Kaufmann. Read the full article at the link below. https://t.co/0COf83OT6B
forbes.com
As emerging therapies develop, I’m cautiously optimistic that we’re nearing breakthroughs in our decades-long quest to stop the body attacking its own tissues and organs.
0
0
5
@HansaBiopharma is excited to welcome Renée Aguiar-Lucander as the Company’s Chief Executive Officer.
0
0
5
For investors and media: Today @HansaBiopharma published its Interim Financial Report for the first quarter of 2025 delivering solid product sales and pipeline progress. Hansa will host a conference call today, 24 April, at 14:00 CEST / 8:00 am ET. https://t.co/fxGCjcR2mV
0
0
0
Join @HansaBiopharma $HNSA for a virtual investor event on June 16 at 14 CEST/8 AM ET with company leadership and KOLs David R. Cornblath, MD and Simon Rinaldi, MRCP, PhD, who will discuss the unmet need and current treatment landscape for GBS. Register: https://t.co/TxwM4d5oHJ
0
1
0
Antibodies, including IgG, are an important part of the immune system. In some situations, including in autoimmune conditions, these antibodies and the antibody-driven immune response, can be harmful and lead to lasting damage to the organs and other parts of the body.
0
0
1
There is a need for better treatment options for rare diseases to improve the quality of patients’ lives and reduce healthcare systems costs. We are committed to advance the science of innovative new treatments to address the unmet need in rare disease. https://t.co/nX1skzj6ue
0
0
3